The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
Open accessPublished version of a preprint
Abstract
Abstract On August 30, 2021, the WHO classified the SARS-CoV-2 Mu variant (B.1.621 lineage) as a new variant of interest. The WHO defines “comparative assessment of virus characteristics and public health risks” as primary action in response to the emergence of new SARS-CoV-2 variants. Here, we demonstrate that the Mu variant is highly resistant to sera from COVID-19 convalescents and BNT162b2-vaccinated individuals. Direct comparison of different SARS-CoV-2 spike proteins revealed that Mu spike is more resistant to serum-mediated neutralization than all other currently recognized variants of interest (VOI) and concern (VOC). This includes the Beta variant (B.1.351) that has been suggested to represent the most resistant variant to convalescent and vaccinated sera to date (e.g., Collier et al, Nature, 2021; Wang et al, Nature, 2021). Since breakthrough infection by newly emerging variants is a major concern during the current COVID-19 pandemic (Bergwerk et al., NEJM, 2021), we believe that our findings are of significant public health interest. Our results will help to better assess the risk posed by the Mu variant for vaccinated, previously infected and naïve populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which is the defining mutation for the B.1.621/Muvariant 27”
From Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 (2022) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S, S. A., Bassi, J., Pinto, D., Fregni, C. S., et al. (2021) · doi:10.1101/2021.01.19.21249840 · Cited by 729
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
Hacisuleyman, E., Hale, C., Saito, Y., Blachere, N. E., Bergh, M., Conlon, E. G., Schaefer-Babajew, D. J., DaSilva, J., Muecksch, F., Gaebler, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105000 · Cited by 716
Flagged first, then by citations
Cited by
Sorted by citations
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Tarke, A., Coelho, C. H., Zhang, Z., Dan, J. M., Yu, E. D., Methot, N., Bloom, N. I., Goodwin, B., Phillips, E., Mallal, S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.015 · Cited by 858
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
Suzuki, R., Yamasoba, D., Kimura, I., Wang, L., Kishimoto, M., Ito, J., Morioka, Y., Nao, N., Nasser, H., Uriu, K., et al. (2022) · Nature · doi:10.1038/s41586-022-04462-1 · Cited by 662
Self-citationActivity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J. J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/s41586-022-04399-5 · Cited by 462
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M., Kohmer, N., Hoehl, S., Helfritz, F. A., et al. (2021) · doi:10.1101/2021.12.07.21267432 · Cited by 440
Lu, L., Mok, B. W.-Y., Chen, L. L., Chan, J. M. C., Tsang, O. T. Y., Lam, B. H. S., Chuang, V. W., Chu, A. W., Chan, W. M., Ip, J. D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1041 · Cited by 396
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
Yamasoba, D., Kimura, I., Nasser, H., Morioka, Y., Nao, N., Ito, J., Uriu, K., Tsuda, M., Zahradník, J., Shirakawa, K., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.035 · Cited by 366
Self-citationTamura, T., Ito, J., Uriu, K., Zahradník, J., Kida, I., Anraku, Y., Nasser, H., Shofa, M., Oda, Y., Lytras, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38435-3 · Cited by 345
Self-citationVirological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
Kimura, I., Yamasoba, D., Tamura, T., Nao, N., Suzuki, T., Oda, Y., Mitoma, S., Ito, J., Nasser, H., Zahradník, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.018 · Cited by 293
Self-citationSARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape
Cele, S., Karim, F., Lustig, G., San, J. E., Hermanus, T., Tegally, H., Snyman, J., Moyo-Gwete, T., Wilkinson, E., Bernstein, M. P., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.01.005 · Cited by 237
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
McLean, G. R., Kamil, J. P., Lee, B., Moore, P. L., Schulz, T. F., Muik, A., Şahin, U., Türeci, Ö., & Pather, S. (2022) · mBio · doi:10.1128/mbio.02979-21 · Cited by 195
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
Saito, A., Tamura, T., Zahradník, J., Deguchi, S., Tabata, K., Anraku, Y., Kimura, I., Ito, J., Yamasoba, D., Nasser, H., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.003 · Cited by 188
Self-citationThe Evolution and Biology of SARS-CoV-2 VariantsPreprint
Telenti, A., Hodcroft, E. B., & Robertson, D. L. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041390 · Cited by 191
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M. E., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F., Bestebroer, T., de Wit, M., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq4450 · Cited by 153
An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain
Greaney, A. J., Starr, T. N., & Bloom, J. D. (2022) · Virus Evolution · doi:10.1093/ve/veac021 · Cited by 147
Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant
Ito, J., Suzuki, R., Uriu, K., Itakura, Y., Zahradník, J., Kimura, K., Deguchi, S., Wang, L., Lytras, S., Tamura, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38188-z · Cited by 146
Self-citationAntibody-mediated neutralization of SARS-CoV-2
Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 150
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Sun, C., Xie, C., Bu, G., Zhong, L., & Zeng, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01039-2 · Cited by 149
Ao, D., He, X., Hong, W., & Wei, X. (2023) · MedComm · doi:10.1002/mco2.239 · Cited by 128
Christensen, P. A., Olsen, R. J., Long, S. W., Subedi, S., Davis, J. J., Hodjat, P., Walley, D. R., Kinskey, J. C., Saavedra, M. O., Pruitt, L., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.10.019 · Cited by 129
SARS-CoV-2: Evolution and Emergence of New Viral Variants
Flores-Vega, V. R., Monroy-Molina, J. V., Jiménez-Hernández, L. E., Torres, A. G., Santos, J. I., & Rosales-Reyes, R. (2022) · Viruses · doi:10.3390/v14040653 · Cited by 127
Zabidi, N. Z., Liew, H. L., Farouk, I. A., Puniyamurti, A., Yip, A. J. W., Wijesinghe, V. N., Low, Z. Y., Tang, J. W.-T., Chow, V. T. K., & Lal, S. K. (2023) · Viruses · doi:10.3390/v15040944 · Cited by 129
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/d41586-021-03846-z · Cited by 114
Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Abulsoud, A. I., El‐Husseiny, H. M., El-Husseiny, A. A., El‐Mahdy, H. A., Ismail, A., Elkhawaga, S. Y., Khidr, E. G., Fathi, D., Mady, E. A., Najda, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113977 · Cited by 112
Virological characteristics of the SARS-CoV-2 BA.2.86 variant
Tamura, T., Mizuma, K., Nasser, H., Deguchi, S., Padilla‐Blanco, M., Oda, Y., Uriu, K., Tolentino, J. E., Tsujino, S., Suzuki, R., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.01.001 · Cited by 108
Self-citationBravo, L. C., Smolenov, I. V., Han, H. H., Li, P., Hosain, R., Rockhold, F. W., Clemens, S. A. C., Roa, C. C., Borja-Tabora, C., Quinsaat, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00055-1 · Cited by 104
Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant
Tamura, T., Irie, T., Deguchi, S., Yajima, H., Tsuda, M., Nasser, H., Mizuma, K., Plianchaisuk, A., Suzuki, S., Uriu, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45274-3 · Cited by 103
Self-citationPopulation immunity predicts evolutionary trajectories of SARS-CoV-2
Meijers, M., Ruchnewitz, D., Eberhardt, J., Łuksza, M., & Lässig, M. (2023) · Cell · doi:10.1016/j.cell.2023.09.022 · Cited by 102
Song, J. Y., Choi, W. S., Heo, J. Y., Lee, J. S., Jung, D. S., Kim, S., Park, K., Eom, J. S., Jeong, S. J., Lee, J., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101569 · Cited by 94
SARS-CoV-2 evolution on a dynamic immune landscape
Raharinirina, N. A., Gubela, N., Börnigen, D., Smith, M. R., Oh, D., Budt, M., Mache, C., Schillings, C., Fuchs, S., Dürrwald, R., et al. (2025) · Nature · doi:10.1038/s41586-024-08477-8 · Cited by 88
Bekliz, M., Adea, K., Vetter, P., Eberhardt, C. S., Hosszu-Fellous, K., Vu, D., Puhach, O., Essaidi-Laziosi, M., Waldvogel‐Abramowski, S., Stephan, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31556-1 · Cited by 86
Newman, J., Thakur, N., Peacock, T. P., Bialy, D., Elrefaey, A. M. E., Bogaardt, C., Horton, D. L., Ho, S., Kankeyan, T., Carr, C., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01163-3 · Cited by 85
Liu, H., Wei, P., Kappler, J. W., Marrack, P., & Zhang, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.825256 · Cited by 84
On the Origins of Omicron’s Unique Spike Gene Insertion
Venkatakrishnan, A., Anand, P., Lenehan, P. J., Suratekar, R., Raghunathan, B., Niesen, M. J. M., & Soundararajan, V. (2022) · Vaccines · doi:10.3390/vaccines10091509 · Cited by 76
Seephetdee, C., Bhukhai, K., Buasri, N., Leelukkanaveera, P., Lerdwattanasombat, P., Manopwisedjaroen, S., Phueakphud, N., Kuhaudomlarp, S., Olmedillas, E., Saphire, E. O., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105370 · Cited by 73
Wang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R., Coggins, S., et al. (2022) · doi:10.1101/2022.07.05.498883 · Cited by 68
Ikemura, N., Taminishi, S., Inaba, T., Arimori, T., Motooka, D., Katoh, K., Kirita, Y., Higuchi, Y., Li, S., Suzuki, T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn7737 · Cited by 62
Wang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R. A., Coggins, S. A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.012 · Cited by 60
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 54
SARS-CoV-2: phenotype, genotype, and characterization of different variants
Saberiyan, M., Karimi, E., Khademi, Z., Movahhed, P., Safi, A., & Ghahfarrokhi, A. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00352-6 · Cited by 56
Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
Wang, Y.-D., Ma, Y., Xu, Y., Liu, J., Li, X., Chen, Y., Chen, Y., Xie, J., Xiao, L., Xiang, Z., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2027219 · Cited by 50
The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant
Kimura, I., Yamasoba, D., Nasser, H., Zahradník, J., Kosugi, Y., Wu, J., Nagata, K., Uriu, K., Tanaka, Y., Ito, J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105720 · Cited by 50
Self-citationYamamoto, M., Gohda, J., Kobayashi, A., Tomita, K., Hirayama, Y., Koshikawa, N., Seiki, M., Semba, K., Akiyama, T., Kawaguchi, Y., et al. (2022) · mBio · doi:10.1128/mbio.00519-22 · Cited by 47
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 48
Desmecht, S., Tashkeev, A., Moussaoui, M. E., Maréchal, N., Perée, H., Tokunaga, Y., Fombellida-Lopez, C., Polese, B., Legrand, C., Wéry, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863554 · Cited by 46
García-Valtanen, P., Hope, C. M., Masavuli, M. G., Yeow, A. E. L., Balachandran, H., Mekonnen, Z. A., Al-Delfi, Z., Abayasingam, A., Agapiou, D., Stella, A. O., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100651 · Cited by 43
Queirós-Reis, L., da Silva, P. G., Gonçalves, J., Brancale, A., Bassetto, M., & Mesquita, J. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910836 · Cited by 40
Liu, H., Wei, P., Zhang, Q., Aviszus, K., Linderberger, J., Yang, J. J., Liu, J., Chen, Z., Waheed, H., Reynoso, L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911325 · Cited by 39
Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
Tulimilli, S. V., Dallavalasa, S., Basavaraju, C. G., Rao, V. K., Chikkahonnaiah, P., Madhunapantula, S. V., & Veeranna, R. P. (2022) · Vaccines · doi:10.3390/vaccines10101751 · Cited by 39
Ju, B., Zheng, Q., Guo, H., Fan, Q., Li, T., Song, S., Sun, H., Shen, S., Zhou, X., Cheng, L., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00638-6 · Cited by 37
Antigenic evolution of SARS coronavirus 2
Mykytyn, A. Z., Fouchier, R. A. M., & Haagmans, B. L. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101349 · Cited by 36
Mohandas, S., Yadav, P. D., Sapkal, G. N., Shete, A. M., Deshpande, G. R., Nyayanit, D. A., Patil, D. Y., Kadam, M., Kumar, A., Mote, C., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103997 · Cited by 39
Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine
Wu, Y., Wang, S., Zhang, Y., Yuan, L., Zheng, Q., Wei, M., Shi, Y., Wang, Z., Ma, J., Wang, K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.011 · Cited by 35
Ikemura, N., Hoshino, A., Higuchi, Y., Taminishi, S., Inaba, T., & Matoba, S. (2021) · medRxiv · doi:10.1101/2021.12.13.21267761 · Cited by 34
Xie, X., 中国科学院昆明动物研究所中国科学院动物模型与人类疾病机理重点实验室, 中.-香., Han, J.-B., Ma, G., Feng, X., Li, X., Zou, Q., Deng, Z., Zeng, J., 中国科学院昆明动物研究所国家昆明高等级生物安全灵长类动物实验中心, 生., et al. (2021) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2021.343 · Cited by 31
Baker, D., MacDougall, A. M., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103448 · Cited by 31
Seki, Y., Yoshihara, Y., Nojima, K., Momose, H., Fukushi, S., Moriyama, S., Wagatsuma, A., Numata, N., Sasaki, K., Kuzuoka, T., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.013 · Cited by 30
YangYang, Gong, X., Yang, L., Li, J., Zhang, J., Wei, L., Ye, G., Tang, Y., Jiang, Y., Li, J., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.01.004 · Cited by 29
Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months
Lopera, T. J., Chvatal‐Medina, M., Flórez‐Álvarez, L., Zapata-Cardona, M. I., Taborda, N. A., Rugeles, M. T., & Hernández, J. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879036 · Cited by 29
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
Xu, S. S., Li, J., Wang, H., Wang, F., Yin, Z., & Wang, Z. (2023) · BMC Medicine · doi:10.1186/s12916-023-02861-3 · Cited by 30
Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Biology · doi:10.3390/biology11121786 · Cited by 27
Choi, J. H., Kim, Y. R., Heo, S. T., Oh, H., Kim, M.-S., Lee, H. R., & Yoo, J. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827306 · Cited by 26
Wang, R., Sun, C., Ma, J., Yu, C., Kong, D., Chen, M., Liu, X., Zhao, D., Gao, S., Kou, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10050702 · Cited by 26
Fratev, F. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01243 · Cited by 25
Paternina-Caicedo, Á. J., Jit, M., Alvis‐Guzmán, N., Fernández, J. C., Hernández, J., Paz-Wilches, J., Rojas-Suárez, J. A., Castell, C. R. D., Alvis-Zakzuk, N. J., Smith, A. D., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100296 · Cited by 25
Genomic epidemiology of SARS-CoV-2 variants during the first two years of the pandemic in Colombia
Jiménez-Silva, C. L., Rivero, R., Douglas, J., Bouckaert, R., Villabona‐Arenas, C. J., Atkins, K. E., Gastelbondo, B., Calderón, A., Guzmán, C., la Hoz, D. E.-D., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00328-3 · Cited by 28
COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines
Biswas, B. K., Chattopadhyay, S., Hazra, S., Hansda, A. K., & Goswami, R. (2022) · Inflammation Research · doi:10.1007/s00011-022-01555-5 · Cited by 25
Inferring variant-specific effective reproduction numbers from combined case and sequencing data
Figgins, M. D., & Bedford, T. (2026) · eLife · doi:10.7554/elife.104802.2 · Cited by 25
Matsui, Y., Li, L., Prahl, M. K., Cassidy, A. G., Özarslan, N., Golan, Y., Gonzalez, V. J., Lin, C. Y., Jigmeddagva, U., Chidboy, M. A., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157354 · Cited by 23
Iwamura, C., Hirahara, K., Kiuchi, M., Ikehara, S. K., Azuma, K., Shimada, T., Kuriyama, S., Ohki, S., Yamamoto, E., Inaba, Y., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203437119 · Cited by 23
Self-citationConvalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update
Chavda, V. P., Bezbaruah, R., Dolia, S., Shah, N., Verma, S., Savale, S. S., & Ray, S. (2023) · Process Biochemistry · doi:10.1016/j.procbio.2023.01.018 · Cited by 25
Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants
Yajima, H., Nomai, T., Okumura, K., Maenaka, K., Ito, J., Hashiguchi, T., Sato, K., Matsuno, K., Nao, N., Sawa, H., et al. (2024) · mBio · doi:10.1128/mbio.03220-23 · Cited by 23
Self-citationZapata-Cardona, M. I., Flórez‐Álvarez, L., Gómez-Gallego, D. M., Moncada-Díaz, M. J., Hernández, J. C., Díaz, F. J., Rugeles, M. T., Aguilar-Jiménez, W., & Zapata, W. (2022) · Iranian Journal of Microbiology · doi:10.18502/ijm.v14i3.9758 · Cited by 21
Duty, J. A., Kraus, T., Zhou, H., Zhang, Y., Shaabani, N., Yildiz, S., Du, N., Singh, A., Miorin, L., Li, D., et al. (2022) · Med · doi:10.1016/j.medj.2022.08.002 · Cited by 21
Wang, Q., Ye, S., Zhou, Z., Li, J., Lv, J., Hu, B., Yuan, S., Qiu, Y., & Ge, X. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28116 · Cited by 21
Álvarez-Díaz, D. A., Muñoz, A. L., Tavera-Rodríguez, P., Herrera-Sepúlveda, M. T., Ruiz-Moreno, H. A., Laiton‐Donato, K., Franco-Muñoz, C., Peláez‐Carvajal, D., Cuellar, D., Muñoz-Suarez, A. M., et al. (2022) · Vaccines · doi:10.3390/vaccines10020180 · Cited by 20
Uriu, K., Cárdenas, P., Muñoz, E. B., Barragán, V., Kosugi, Y., Shirakawa, K., Takaori‐Kondo, A., Ito, J., Yamasoba, D., Kimura, I., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac053 · Cited by 20
Self-citationCOVID-19 Genetic Variants and Their Potential Impact in Vaccine Development
Giau, V. V., Bagyinszky, E., & An, S. S. A. (2022) · Microorganisms · doi:10.3390/microorganisms10030598 · Cited by 21
Chang, M., Ke, H., Coherd, C. D., Wang, Y., Mashima, K., Kastrunes, G. M., Huang, C., & Marasco, W. A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104025 · Cited by 20
Guo, D., Duan, H., Cheng, Y., Wang, Y., Hu, J., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00074-3 · Cited by 17
Zhou, H., Ni, W., Huang, W., Wang, Z., Cai, M., & Sun, Y.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834942 · Cited by 17
Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type
Dingemans, J., van der Veer, B. M. J. W., Gorgels, K. M. F., Hackert, V., Hensels, A. Y. J., den Heijer, C. D. J., Hoebe, C. J. P. A., Savelkoul, P. H. M., & van Alphen, L. B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1027271 · Cited by 19
Description of a One-Year Succession of Variants of Interest and Concern of SARS-CoV-2 in Venezuela
Jaspe, R. C., Loureiro, C. L., Sulbarán, Y. F., Moros, Z., D’Angelo, P., Hidalgo, M., Rodríguez, L., Alarcón, V., Aguilar, M., Sánchez, D., et al. (2022) · Viruses · doi:10.3390/v14071378 · Cited by 16
What makes SARS‐CoV‐2 unique? Focusing on the spike protein
Qian, J., Zhang, S.-C., Wang, F., Li, J., & Zhang, J. (2024) · Cell Biology International · doi:10.1002/cbin.12130 · Cited by 16
Virion morphology and on-virus spike protein structures of diverse SARS-CoV-2 variants
Ke, Z., Peacock, T. P., Brown, J. C., Sheppard, C., Croll, T. I., Kotecha, A., Goldhill, D. H., Barclay, W., & Briggs, J. A. G. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00303-1 · Cited by 16
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
Ambrosino, D. M., Han, H. H., Hu, B. T., Liang, J. G., Clemens, R. L., Johnson, M., Siber, G. R., & Goldblatt, D. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab574 · Cited by 16
Delshad, M., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109128 · Cited by 18
Evasion of Vaccine-Induced Humoral Immunity by Emerging Sub-Variants of SARS-CoV-2
Koyama, T., Miyakawa, K., Tokumasu, R., Jeremiah, S. S., Kudo, M., & Ryo, A. (2022) · Future Microbiology · doi:10.2217/fmb-2022-0025 · Cited by 15
Dispersion patterns of SARS-CoV-2 variants Gamma, Lambda and Mu in Latin America and the Caribbean
Gräf, T., Martínez, A. A., Bello, G., Dellicour, S., Lemey, P., Colizza, V., Mazzoli, M., Poletto, C., Cardoso, V. L. O., da Silva, A. F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46143-9 · Cited by 16
Simulation of future COVID-19 epidemic by vaccination coverage scenarios in Japan
Furuse, Y. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05025 · Cited by 16
Focosi, D., Franchini, M., Joyner, M. J., & Casadevall, A. (2022) · Vox Sanguinis · doi:10.1111/vox.13239 · Cited by 15
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
Darling, T. L., Ying, B., Whitener, B. M., VanBlargan, L. A., Bricker, T. L., Liang, C.-Y., Joshi, A., Bamunuarachchi, G., Seehra, K., Schmitz, A. J., et al. (2022) · Med · doi:10.1016/j.medj.2022.03.009 · Cited by 15
Al-Rashedi, N. A. M., Alburkat, H., Hadi, A. O., Munahi, M. G., Jasim, A., Hameed, A., Oda, B. S., Lilo, K. M., AlObaidi, L. A. H., Vapalahti, O., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267295 · Cited by 15
Giron, C. C., Laaksonen, A., & da Silva, F. L. B. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2095305 · Cited by 18
Lanza, F., Monaco, F., Ciceri, F., Cairoli, R., Sacchi, M. V., Guidetti, A., Marchetti, M., Massaia, M., Arcaini, L., Krampera, M., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3060 · Cited by 15
Rapid SARS-CoV-2 Variants Enzymatic Detection (SAVED) by CRISPR-Cas12a
Yang, J., Barua, N., Rahman, M. N., Li, C., Lo, N. W. S., Yeong, K.-Y., Tsang, T. F., Yang, X., Cheung, Y., Tsang, A. K. L., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.03260-22 · Cited by 15
Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G., Tomov, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11071181 · Cited by 16
Virological characteristics correlating with SARS-CoV-2 spike protein fusogenicity
Begum, M. M., Ichihara, K., Takahashi, O., Nasser, H., Jonathan, M., Tokunaga, K., Yoshida, I., Nagashima, M., Sadamasu, K., Yoshimura, K., et al. (2024) · Frontiers in Virology · doi:10.3389/fviro.2024.1353661 · Cited by 14
Self-citation
Metadata
- Authors
- Uriu, K., Kimura, I., Shirakawa, K., Takaori-Kondo, A., Nakada, T.-A., Kaneda, A., Nakagawa, S., & Sato, K.
- Affiliations
- The University of Tokyo (JP)
- Kyoto University (JP)
- Chiba University (JP)
- Tokai University (JP)
- Corresponding author
- Sato, Kei
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-16
- Volume
- 385
- Issue
- 25
- Pages
- 2397-2399
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8609602
- OpenAlex
- W3208271747
- Cited by
- 214
- References
- 4
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 14 · 2023: 39 · 2022: 120 · 2021: 30
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (20fk0108451)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, Mu variant, Omicron variant, neutralizing antibodies, convalescent serum, COVID-19 vaccines, vaccine-induced immunity, antibody neutralization
- MeSH terms
- COVID-19, SARS-CoV-2, BNT162 Vaccine, COVID-19 Serotherapy, Colombia, Humans, Immunization, Passive, Neutralization Tests, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
